SUPN - SUPERNUS PHARMACEUTICALS, INC.
IEX Last Trade
35.61
3.780 10.615%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$31.83
3.78
11.88%
Fundamental analysis
26%
Profitability
7%
Dept financing
35%
Liquidity
75%
Performance
30%
Performance
5 Days
0.48%
1 Month
-1.39%
3 Months
18.90%
6 Months
34.29%
1 Year
21.79%
2 Year
-4.99%
Key data
Stock price
$35.61
DAY RANGE
$31.83 - $35.30
52 WEEK RANGE
$26.04 - $39.37
52 WEEK CHANGE
$19.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Jack A. Khattar
Region: US
Website: supernus.com
Employees: 580
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: supernus.com
Employees: 580
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Supernus Pharmaceuticals, Inc. focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the. treatment of epilepsy, as well as for the prophylaxis of migraine headache. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
Recent news